A case of hepatitis C-associated osteosclerosis: accelerated bone turnover controlled by pulse steroid therapy. (12th November 2016)

• Record Type: Journal Article
• Authors: Miyamura, Nobuhiro; Nishida, Shuhei; Itasaka, Mina; Matsuda, Hirofumi; Ohtou, Takeshi; Yamaguchi, Yasuhiro; Inaba, Daisuke; Tamiya, Sadahiro; Nakano, Tetsuo
• Is Part Of: Endocrinology, diabetes & metabolism case reports. (2016)
• Publication Date: 2016-11-12
• Subjects: Adult -- Male -- Asian - Japanese -- Japan; Bone -- Bone -- Osteosclerosis -- Hepatitis C; Bone pain -- Leg pain -- Osteosclerosis -- Hypocalciuria -- Bone biopsy -- Ultrasound scan -- Bone scintigraphy -- DEXA scan -- Parathyroid scintigraphy -- Trabecular thickness -- Bone mineral density -- Bone mineral content -- Calcium (serum) -- PTH -- Calcifediol -- Calcitriol -- Deoxypyridinoline -- Osteocalcin -- Transaminase -- Alkaline phosphatase (bone-specific) -- Alkaline phosphatase -- Calcium to creatinine clearance ratio -- NTX -- TRAP 5b -- C1NP -- IGF1 -- Alanine aminotransferase -- Steroids -- Antivirals -- Bisphosphonates -- Corticosteroids -- Methylprednisolone -- Prednisolone -- Glucocorticoids -- Risedronate -- Alphacalcidol -- Calcium-L-aspartate -- Calcium carbonate; Radiology/Rheumatology; Unique/unexpected symptoms or presentations of a disease -- November -- 2016; Endocrinology -- Periodicals; Diabetes -- Periodicals; Diabetes Mellitus; Endocrinology; Diabetes; Endocrinology; Case Reports; Periodicals; Periodicals; 616.4
• DOI: 10.1530/EDM-16-0097
• Languages: English
• ISSNs: 2052-0573

Abstract

Summary: Hepatitis C-associated osteosclerosis (HCAO), a very rare disorder in which an extremely rapid bone turnover occurs and results in osteosclerosis, was acknowledged in 1990s as a new clinical entity with the unique bone disorder and definite link to chronic type C hepatitis, although the pathogenesis still remains unknown. Affected patients suffer from excruciating deep bone pains. We report the 19th case of HCAO with diagnosis confirmed by bone biopsy, and treated initially with a bisphosphonate, next with corticosteroids and finally with direct acting antivirals (DAA: sofosbuvir and ribavirin) for HCV infection. Risedronate, 17.5 mg/day for 38 days, did not improve the patient's symptoms or extremely elevated levels of bone markers, which indicated hyper-bone-formation and coexisting hyper-bone-resorption in the patient. Next, intravenous methylprednisolone pulse therapy followed by high-dose oral administration of prednisolone evidently improved them. DAA therapy initiated after steroid therapy successfully achieved sustained virological response, but no additional therapeutic effect on them was observed. Our results strongly suggested that the underlying immunological alteration is the crucial key to clarify the pathogenesis of HCAO. Bone mineral density of lumbar vertebrae of the patient was increased by 14% in four-month period of observation. Clarification of the mechanisms that develop osteosclerosis in HCAO might lead to a new therapeutic perspective for osteoporosis. Learning points: HCAO is an extremely rare bone disorder, which occurs exclusively in patients affected with HCV, of which only 18 cases have been reported since 1992 and pathogenesis still remains unclear. Pathophysiology of HCAO is highly accelerated rates of both bone formation and bone resorption, with higher rate of formation than that of resorption, which occur in general skeletal leading to the diffuse osteosclerosis with severe bone pains. Steroid therapy including intravenous pulse administration in our patient evidently ameliorated his bone pains and reduced elevated values of bone markers. This was the first successful treatment for HCAO among cases reported so far and seemed to propose a key to solve the question for its pathogenesis. The speed of increase in the bone mineral content of the patient was very high, suggesting that clarification of the mechanism(s) might lead to the development of a novel therapy for osteoporosis.